Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Salidroside (rhodioloside) is a phenylpropanoid glycoside derived primarily from Rhodiola rosea root, comprising a tyrosol aglycone linked to a glucose moiety. It exerts adaptogenic, antioxidant, and potential anticancer effects primarily through modulation of the MAPK signaling cascade, LOX-1 downregulation, and upregulation of superoxide dismutase (SOD) expression.
Origin & History
Salidroside (also known as rhodioloside) is a phenyl ethanol glycoside compound extracted primarily from the roots of Rhodiola rosea L., a perennial flowering plant native to cold regions of Europe and Asia. It is isolated through standard solvent extraction methods from R. rosea extracts like SHR-5, followed by purification processes.
Research Narrative (Provisional)
The research dossier reveals a significant gap in human clinical evidence, with no PubMed PMIDs for human trials, RCTs, or meta-analyses provided. Current evidence is limited to preclinical studies, including in vitro cancer cell inhibition and animal models for arthritis and exercise performance.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Salidroside (Rhodioloside) is a pure isolated phenylpropanoid glycoside compound (molecular formula C14H20O7, molecular weight 300.30 g/mol), not a food ingredient, and therefore carries no macronutrient, micronutrient, vitamin, mineral, or fiber content. As a bioactive compound, it is the primary active constituent of Rhodiola rosea root, typically present in standardized Rhodiola extracts at 0.5–3% by weight (dry root contains approximately 0.3–1.0% salidroside by weight). It consists structurally of a tyrosol aglycone unit linked to a glucose moiety via a beta-glycosidic bond. Research-grade and supplement-grade preparations are typically >98% pure isolated compound. Bioavailability data from rodent pharmacokinetic studies indicates oral bioavailability is moderate; salidroside is absorbed in the small intestine, partially hydrolyzed to tyrosol by intestinal and hepatic enzymes, with peak plasma concentrations (Cmax) reached at approximately 0.5–1 hour post-ingestion in animal models. It undergoes hepatic glucuronidation and sulfation. No caloric value is applicable at physiological doses (typically studied at 50–500 mg/kg in animal models; human supplement doses commonly range 50–200 mg/day of standardized extract containing defined salidroside percentages). No protein, fat, carbohydrate, or micronutrient content is attributable to this isolated compound.
Reported Mechanism (Provisional)
Salidroside inhibits the mitogen-activated protein kinase (MAPK) pathway — including ERK1/2, p38, and JNK phosphorylation — thereby reducing pro-inflammatory cytokine transcription. It downregulates lectin-like oxidized LDL receptor-1 (LOX-1), attenuating oxidative stress-driven NF-κB activation and vascular inflammation. Additionally, salidroside upregulates superoxide dismutase (SOD) and catalase enzymatic activity, enhancing cellular reactive oxygen species (ROS) scavenging capacity and protecting mitochondrial membrane integrity.
Clinical Narrative (Provisional)
The majority of salidroside research consists of in vitro cell-line studies and rodent preclinical models, with limited randomized controlled trials isolating salidroside specifically from whole Rhodiola rosea extracts. Anticancer evidence derives from cell-line experiments showing IC50 values of 71–264 μg/mL across bladder cancer lines (RT4, J82, T24, UMUC3, 5637), which does not reliably translate to human therapeutic dosing. Some human trials using standardized Rhodiola rosea extract (containing 1–3% salidroside, typically 200–600 mg/day) have demonstrated reductions in fatigue and stress biomarkers such as cortisol, but these outcomes cannot be attributed solely to salidroside. Overall, evidence quality is preliminary to moderate; robust phase II/III clinical trials specifically investigating isolated salidroside are lacking.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.